FIG 1.

Development of a bioactive small molecule high-throughput screen for the identification of host factors regulating ZIKV infection. (A) Schematic view of the screening workflow. Briefly, SNB-19 cells were plated in 96-well plates 36 h prior to treatment with 2,659 bioactive compounds and infection with ZIKV (SZ01) for 48 h, followed by fixation and staining. The final concentration of the compounds was 5 μM, and three duplicates were tested for each compound. The infection ratio was normalized and calculated with DMSO as a negative control across screening plates. Representative hits were further evaluated at concentrations of 200 nM, 1 μM, and 5 μM and categorized into two groups with inhibitory (B) or enhancing (C) effects on ZIKV infection.